Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

A major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function

Shannon L. Meeks, Courtney L. Cox, John F. Healey, Ernest T. Parker, Bhavya S. Doshi, Bagirath Gangadharan, Rachel T. Barrow, Pete Lollar

Blood (2012) 120 (12): 2512–2520.

https://doi.org/10.1182/blood-2012-02-412361

Published: 2012

Includes: Supplemental data

Journal Articles

Factor VIII Structure, Not Activity, Is the Primary Determinant of Immunogenicity in Hemophilia A and Combined Hemophilia A/Von Willebrand Disease Mice

Shannon L. Meeks, MD, Courtney Cox, M.S., John F. Healey, B.S., Ernest T Parker, B.A., Bagirath Gangadharan, MS, Rachel T. Barrow, BS, John (Pete) S. Lollar, III, M.D.

Blood (2011) 118 (21): 1187.

https://doi.org/10.1182/blood.V118.21.1187.1187

Published: 2011

Journal Articles

Non-Classical Anti-Factor VIII C2 Domain Antibodies Are Pathogenic in a Murine in Vivo Bleeding Model.

Shannon Meeks, MD, John F. Healey, BS, Ernest T. Parker, BS, Rachel T. Barrow, BS, John (Pete) Lollar, MD

Blood (2008) 112 (11): 2027.

https://doi.org/10.1182/blood.V112.11.2027.2027

Published: 2008

Journal Articles

Nonclassical anti-C2 domain antibodies are present in patients with factor VIII inhibitors

Shannon L. Meeks, John F. Healey, Ernest T. Parker, Rachel T. Barrow, Pete Lollar

Blood (2008) 112 (4): 1151–1153.

https://doi.org/10.1182/blood-2008-01-132639

Published: 2008

Journal Articles

Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation

Shannon L. Meeks, John F. Healey, Ernest T. Parker, Rachel T. Barrow, Pete Lollar

Blood (2007) 110 (13): 4234–4242.

https://doi.org/10.1182/blood-2007-06-096842

Published: 2007

Journal Articles

Enhanced Anticoagulant Activity of Factor VIII Inhibitors Due to Positive Cooperativity between Two Classes of Anti-Factor VIII C2 Antibodies.

Shannon L. Meeks, MD, John F. Healey, BS, Rachel T. Barrow, BS, Ernest T. Parker, BS, Pete Lollar, MD

Blood (2007) 110 (11): 784.

https://doi.org/10.1182/blood.V110.11.784.784

Published: 2007

Journal Articles

Non-Classical Anti-Factor VIII C2 Domain Inhibitors Are Present in the Plasmas of Most Factor VIII Inhibitor Patients.

Shannon L. Meeks, MD, John F. Healey, BS, Rachel T. Barrow, BS, Ernest T. Parker, BS, Pete Lollar

Blood (2007) 110 (11): 786.

https://doi.org/10.1182/blood.V110.11.786.786

Published: 2007

Journal Articles

Differential Immunodominance of Human and Porcine Factor VIII in Hemophilia A Mice.

John F. Healey, B.S., Ernest T. Parker, B.S., Rachel T. Barrow, B.S., Pete Lollar, M.D.

Blood (2004) 104 (11): 40.

https://doi.org/10.1182/blood.V104.11.40.40

Published: 2004

Journal Articles

Reduction of the inhibitory antibody response to human factor VIII in hemophilia A mice by mutagenesis of the A2 domain B-cell epitope

Ernest T. Parker, John F. Healey, Rachel T. Barrow, Heather N. Craddock, Pete Lollar

Blood (2004) 104 (3): 704–710.

https://doi.org/10.1182/blood-2003-11-3891

Published: 2004

Journal Articles

Antigenicity of putative phospholipid membrane-binding residues in factor VIII

Rachel T. Barrow, John F. Healey, Marc G. Jacquemin, Jean-Marie R. Saint-Remy, Pete Lollar

Blood (2001) 97 (1): 169–174.

https://doi.org/10.1182/blood.V97.1.169

Published: 2001

Journal Articles

Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules

Rachel T. Barrow, John F. Healey, David Gailani, Dorothea Scandella, Pete Lollar

Blood (2000) 95 (2): 564–568.

https://doi.org/10.1182/blood.V95.2.564

Published: 2000

Journal Articles

Residues Glu2181-Val2243 Contain a Major Determinant of the Inhibitory Epitope in the C2 Domain of Human Factor VIII

John F. Healey, Rachel T. Barrow, Hiba M. Tamim, Ira M. Lubin, Midori Shima, Dorothea Scandella, Pete Lollar

Blood (1998) 92 (10): 3701–3709.

https://doi.org/10.1182/blood.V92.10.3701

Published: 1998

NARROW

A major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function

Factor VIII Structure, Not Activity, Is the Primary Determinant of Immunogenicity in Hemophilia A and Combined Hemophilia A/Von Willebrand Disease Mice

Non-Classical Anti-Factor VIII C2 Domain Antibodies Are Pathogenic in a Murine in Vivo Bleeding Model.

Nonclassical anti-C2 domain antibodies are present in patients with factor VIII inhibitors

Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation

Enhanced Anticoagulant Activity of Factor VIII Inhibitors Due to Positive Cooperativity between Two Classes of Anti-Factor VIII C2 Antibodies.

Non-Classical Anti-Factor VIII C2 Domain Inhibitors Are Present in the Plasmas of Most Factor VIII Inhibitor Patients.

Differential Immunodominance of Human and Porcine Factor VIII in Hemophilia A Mice.

Reduction of the inhibitory antibody response to human factor VIII in hemophilia A mice by mutagenesis of the A2 domain B-cell epitope

Antigenicity of putative phospholipid membrane-binding residues in factor VIII

Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules

Residues Glu2181-Val2243 Contain a Major Determinant of the Inhibitory Epitope in the C2 Domain of Human Factor VIII

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only